ORTHOCELL ORD
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.
Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap
Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month. The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption. Orthocell has secured […]
Orthocell’s Remplir Used by Australian Urologists in Prostate Cancer Surgery
Regenerative medicine company Orthocell (ASX: OCC) has introduced its flagship nerve repair device Remplir to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Currently up to 80% of men experience erectile dysfunction and up to 35% suffer from urinary incontinence after radical prostatectomy due to damage of the peripheral nerves in the neurovascular […]
Orthocell Posts Record Full-Year Revenue, Takes Remplir and Striate into New Global Markets
Regenerative medicine company Orthocell (ASX: OCC) has reported a record revenue of $9.19 million for the 12 months to the end of June 2025, underscoring market penetration and sales growth of its flagship nerve repair product Remplir in Australia. The figure was up 35.8% on the previous financial year — boosted by $2.73m revenue in […]